Dr. Meisel on Managing Toxicities Associated with T-DM1 in HER2+ Breast Cancer
Jane L. Meisel, MD, discusses managing toxicities associated with ado-trastuzumab emtansine in patients with HER2-positive breast cancer.
Related Articles
Potent Oral Agent Acting as Immunotherapy and Targeted Treatment Produces High Response Rate in Certain Patients
A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone…
Northwestern Medicine Launches a Hispanic Program for Patients With Lung and Thoracic Diseases
The Northwestern Medicine Canning Thoracic Institute Hispanic Program was recently launched to offer personalized care for lung and thoracic patients in their native language, making…
Dr Cannon on Improving Responses With Immunotherapy in Ovarian Cancer
Martin Cannon, PhD, discusses explanations for the lack of success with immune checkpoint inhibitors in ovarian cancer, and how to potentially improve responses to immunotherapy…
Radical Cystectomy or Bladder Preservation: Understanding Optimal Therapy for Locally Advanced Bladder Cancer
Neil Desai, MD, MHS, expands on the need for further research regarding potential treatment strategies for patients with locally advanced, nonmetastatic muscle-invasive bladder cancer who…
Fox Chase Researcher Receives Grant for Study of RNA, Telomerase and Implications for Disease
A Fox Chase Cancer Center researcher has been awarded a $2.5 million grant from the National Institute of General Medical Sciences to investigate RNA structure…
Frontline Zanidatamab Plus Docetaxel Yields Antitumor Activity, Safety in Advanced HER2+ Breast Cancer
The novel HER2-targeted bispecific antibody zanidatamab in combination with docetaxel demonstrated efficacy with a manageable safety profile as first-line treatment in patients with advanced HER2-positive…
Bredel Findings Address Understanding of Diffuse Gliomas
A groundbreaking discovery by Markus Bredel, MD, PhD, and colleagues not only marks a significant milestone in our understanding of diffuse gliomas but also paves…
Teclistamab Plus Nirogacestat Elicits Durable Responses in Relapsed/Refractory Myeloma
The combination of teclistamab and nirogacestat produced high and deep responses in patients with relapsed/refractory multiple myeloma.
Early Efficacy of BL-B01D1 in a Phase 1 Study Reflects Potential for ADCs in Lung Cancer and Beyond
Helena A. Yu, MD, discusses the investigation of BL-B01D1 in patients with advanced solid tumors, the potential significance of this research for those with EGFR-mutant…
LITESPARK-024 Trial to Examine HIF-2α and CDK4/6 Inhibition With Belzutifan Plus Palbociclib in Advanced RCC
David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and…